XM levert geen diensten aan inwoners van de Verenigde Staten.
A
A

Amgen


Nieuws

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Baker Hughes Co BKR.OQ +4.8% Diamondback Energy Inc FANG.OQ +4.2% Amgen Inc AMGN.OQ +2.9% MongoDB Inc MDB.OQ +2.7% Mondelez International Inc MDLZ.OQ +2.6% Bottom Performers Percent Change Dexcom Inc DXCM.OQ -5.5% NVIDIA Corp NVDA.OQ -5.4% Arm Holdings PLC ARM.OQ -5.1% Marvell Technology Inc MRVL.OQ -4.7% Qualcomm Inc QCOM.OQ -4.4% The Nasdaq 100 .NDX lost 157.25 points, or 0.80%,
A
M
M
N
Q
U
D
D

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Baker Hughes Co BKR.OQ +3.4% Moderna Inc MRNA.OQ +2.8% Diamondback Energy Inc FANG.OQ +2.7% Mondelez International Inc MDLZ.OQ +2.4% Amgen Inc AMGN.OQ +2.2% Bottom Performers Percent Change Arm Holdings PLC ARM.OQ -4.7% NVIDIA Corp NVDA.OQ -4.6% Dexcom Inc DXCM.OQ -3.8% Qualcomm Inc QCOM.OQ -3.6% Marvell Technology Inc MRVL.OQ -3.5% The Nasdaq 100 .NDX lost 59.24 points, or 0.30%,
A
M
M
N
Q
U
D
D

US FDA approves Roche's drug for a chronic blood disorder (June 21)

CORRECTED-UPDATE 1-US FDA approves Roche's drug for a chronic blood disorder (June 21) Removes dated comment from chief medical officer in paragraph 6 of June 21 story June 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S drug for a chronic blood disorder, the Swiss drugmaker said. The drug crovalimab, branded as PiaSky, is a monthly under-the-skin or intravenous treatment for paroxysmal nocturnal hemoglobinuria (PNH).
A
A
R

FDA Approves Blincyto® (Blinatumomab) In Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) In The Consolidation Phase

BRIEF-FDA Approves Blincyto® (Blinatumomab) In Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) In The Consolidation Phase Amgen Inc AMGN.O : FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSO
A

U.S. Adobe, Oracle, Zscaler

U.S. RESEARCH ROUNDUP-Adobe, Oracle, Zscaler June 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Oracle Corp and Zscaler, on Friday. HIGHLIGHTS * Adobe Inc ADBE.O : Baird raises target price to $545 from $525 * Bandwidth Inc BAND.O : Morgan Stanley cuts to underweight from equal-weight * Corpay Inc CPAY.N : Jefferies cuts target price to $295 from $330 * Oracle Corp ORCL.N : Berenberg raises target price t
A
A
A
B
H
H
M
B
C
D

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

AbbVie's tight grip on Humira market raises concerns about biosimilars

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
A
C
P
T
F

Amgen's drug meets main goal in late-stage study for rare disease

UPDATE 2-Amgen's drug meets main goal in late-stage study for rare disease Adds details in paragraphs 5-7, sales of the drug in paragraph 8, analyst comment in paragraph 11 By Sriparna Roy June 5 (Reuters) - Amgen AMGN.O said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, meeting the main goal of a late-stage study.
A

Amgen Announces Positive Results For Phase 3 Registrational Trial Evaluating Uplizna For Treatment Of Immunoglobulin G4-Related Disease

BRIEF-Amgen Announces Positive Results For Phase 3 Registrational Trial Evaluating Uplizna For Treatment Of Immunoglobulin G4-Related Disease June 5 (Reuters) - Amgen Inc AMGN.O : AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) AMGEN INC - FIRST RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO DEMONSTRATE BENEFIT IN IGG4-RD AMGEN INC - DATA SHOW A STATISTICALLY SIGNIFICANT 87% REDUCTION
A

Amgen's drug meets main goal in late-stage study for immune-system related condition

Amgen's drug meets main goal in late-stage study for immune-system related condition June 5 (Reuters) - Amgen AMGN.O said on Wednesday its drug to treat patients with an immune-system related condition has met the main goal of a late-stage study. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
A

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R

Novo Nordisk notches perfect 10

LIVE MARKETS-Novo Nordisk notches perfect 10 STOXX 600 little changed Tech leads fallers Euro zone CPI hotter than forecast S&P futures fall Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com NOVO NORDISK NOTCHES PERFECT 10 Novo Nordisk, Europe's largest company by market cap, looks set to have extended its run of monthly gains to 10 in May, currently eking out an almost 2% rise, bu
A
E
J
U
U

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

UPDATE 1-US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment Adds details in paragraphs 7, 8 May 28 (Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's AMGN.O Bkemv, the first biosimilar to AstraZeneca's AZN.L rare blood disorder treatment Soliris. Amgen's drug will be marketed under the name Bkemv.
A
A

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment May 28 (Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's AMGN.O Bkemv, the first biosimilar to AstraZeneca's AZN.L rare blood disorder treatment Soliris. Amgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex biological drugs.
A
A

U.S. FDA Approves Amgen Inc's Bkemv - Website

BRIEF-U.S. FDA Approves Amgen Inc's Bkemv - Website Amgen Inc AMGN.O : U.S. FDA APPROVES AMGEN INC'S BKEMV - WEBSITE FDA: AMGEN INC'S BKEMV (ECULIZUMAB-AEEB) IS BIOSIMILAR TO SOLIRIS (ECULIZUMAB) U.S. FDA: AMGEN'S BKEMV (ECULIZUMAB-AEEB) COMES WITH BOXED WARNING Source text for Eikon: [ID:] Further company coverage: AMGN.O
A

Weight-loss drug forecasts jump to $150 billion as supply grows

ANALYSIS-Weight-loss drug forecasts jump to $150 billion as supply grows By Deena Beasley May 28 (Reuters) - As millions seek access to weight-loss drugs from Novo Nordisk NOVOb.CO and Eli Lilly LLY.N , increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.
A

Alvotech rises on higher Q1 revenue

BUZZ-Alvotech rises on higher Q1 revenue ** Shares of biotech company Alvotech SA ALVO.O rise 4.8% to $14.61 after the bell ** Co reports Q1 total revenue of $36.9 mln vs $15.9 mln a year ago ** Raises 2024 topline revenue forecast to $400-$500 mln, tightens outlook for bottom line to $100-$150 mln ** Reports Q1 net loss of $218.7 mln vs $276.2 mln a year ago ** Co said earlier on Tuesday it had entered into an agreement with Dr.
A

U.S. STOCKS ProShares Ether, International Business Machines, Alvotech

BUZZ-U.S. STOCKS ON THE MOVE-ProShares Ether, International Business Machines, Alvotech Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. indexes oscillated within a tight range on Tuesday as investors grew cautious ahead of AI chip leader Nvidia's earnings this week and Federal Reserve officials emphasized the central bank was in no hurry to ease interest rates.
A
E
M
N
T
U
U
E
G
K
L

Alvotech rises on deal with Dr Reddy's on biosimilar to Amgen's bone drugs

BUZZ-Alvotech rises on deal with Dr Reddy's on biosimilar to Amgen's bone drugs ** Alvotech's ALVO.O shares rise 2.2% to $13.80 ** Co says it has entered into an agreement with Dr. Reddy's Laboratories REDY.NS to commercialize a biosimilar to Amgen's AMGN.O bone disease drugs Prolia and Xgeva ** The deal includes an upfront payment to ALVO with additional payments upon meeting certain milestones ** REDY will get exclusive commercialization rights for the drug AVT03 in the U.S.
A



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.